Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

One place this happens is around the belly button, where tiny veins in the abdominal wall expand and become visible under the ...

Three common medical conditions may explain why some heavy drinkers develop advanced liver disease while others do not, ...

The following is a summary of "Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD)," published in ...

Researchers developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic ...

Low-Level Traffic Air Pollution Linked to Liver Damage and Fatty Liver Disease Jan. 31, 2025 — Low levels of traffic-related air pollution harms the liver and may raise the risk of metabolic ...

A doctor who specialises in diseases and diet has urged people with a fatty liver to incorporate five drinks into the their daily routine. By doing so, he says they will help remove fat from the ...